Clinical predictive factors of unresponsiveness to omalizumab in patients with chronic spontaneous urticaria.

Clinical predictive factors of unresponsiveness to omalizumab in patients with chronic spontaneous urticaria. Br J Dermatol. 2020 Jun 12;: Authors: Castagna J, Bernard L, Hacard F, Delcroix F, Darrigade AS, Nicolas JF, Decullier E, Nosbaum A, Bérard F Abstract Chronic spontaneous urticaria (CSU) is an inflammatory disease which is characterized by spontaneous appearance of wheals (hives), angioedema or both for at least six weeks. Approximately 10% of patients suffering from CSU are unresponsive to second-generation H1-antihistamines. For these severe cases, recommendation is a treatment by omalizumab (OMZ) -a humanized anti-IgE monoclonal antibody. However, approximately 20% of patients are still non-responders to OMZ. PMID: 32531805 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research